Dr. Culver discusses the organization's work at ASCO and the importance of having a patient advocacy presence at the meeting.
ALK+ Non-Small Cell Lung Cancer
Phase 2 of the study investigated the targeted therapy in treatment-naive patients with stage III ALK-positive disease.
Dr. Shaw is being recognized for her "groundbreaking work in defining ALK- and ROS1-positive lung cancers," officials said.
The long-term follow-up data shows that PFS remains unreached in the subgroup of Asian patients in the CROWN study.
The 12-member board will guide the guide the patient-driven organization’s research and strategic priorities.
The phase 2 trial included patients who had advanced or metastatic NSCLC with actionable genomic alterations.
Shirish M. Gadgeel, MD, discusses the phase 1/2 ARROS-1 and ALKOVE-1 studies presented at the ESMO 2024 Congress.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
The efficacy of ensartinib was evaluated in eXALT3, an open-label, randomized, active-controlled, multicenter trial.
Ken Culver, MD, Director of Research and Clinical Affairs at ALK Positive, discusses the on-going ALK Life Study.
Dr. Paz-Ares shares his insights on recent studies and highlights practice-changing data in lung cancer.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.